Price
$14.41
Increased by +0.05%
Dollar Volume (20D)
8.70 M
ADR%
9.79
Earnings Report Date (estimate)
May 11, 23 (N/A)
Market Cap.
795.86 M
Shares Float
8.70 M
Shares Outstanding
55.23 M
Beta
0.00
Price / Earnings
-8.90
BPR
5.69 K
20D Range
10.81 15.29
50D Range
7.22 15.29
200D Range
0.38 15.29
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Aug 29, 22 -1.33 -0.08
Decreased by -19.53 K%
Apr 26, 22 -0.48 -0.09
Decreased by -4.81 K%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 24.00 K
Decreased by -98.51%
-15.30 M
Increased by +32.43%
Decreased by -63.76 K%
Decreased by -4.44 K%
Dec 31, 22 2.25 M
Increased by +93.28%
-13.25 M
Increased by +37.47%
Decreased by -590.36%
Increased by +67.65%
Sep 30, 22 2.25 M
Increased by +93.28%
-13.25 M
Increased by +32.15%
Decreased by -590.36%
Increased by +64.90%
Jun 30, 22 1.30 M
Decreased by -49.38%
-28.84 M
Decreased by -98.84%
Decreased by -2.22 K%
Decreased by -292.79%
Mar 31, 22 1.61 M
Decreased by -37.14%
-22.65 M
Decreased by -56.13%
Decreased by -1.40 K%
Decreased by -148.38%
Dec 31, 21 1.16 M
Decreased by -67.70%
-21.19 M
Decreased by -281.60%
Decreased by -1.82 K%
Decreased by -1.08 K%
Sep 30, 21 1.16 M
Decreased by -67.70%
-19.53 M
Decreased by -251.72%
Decreased by -1.68 K%
Decreased by -988.77%
Jun 30, 21 2.57 M
Decreased by -20.80%
-14.51 M
Decreased by -433.76%
Decreased by -565.28%
Decreased by -573.96%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.